Welcome to LookChem.com Sign In|Join Free
  • or
2-Chloro-5-methyl-4-nitropyridine-N-oxide is a chemical compound with the formula C6H5ClN2O3. It is characterized by its molecular weight of 188.57 g/mol and its boiling point ranges from 346.921 to 408.032 °C at 760 mmHg. 2-CHLORO-5-METHYL-4-NITROPYRIDINE-N-OXIDE is notable for its nitropyridine component, and the N-Oxide component. The Chloro and Methyl functional groups denote the presence of chlorine and a single carbon and hydrogen respectively. It's crucial to handle 2-CHLORO-5-METHYL-4-NITROPYRIDINE-N-OXIDE carefully due to its reactivity and potential for harm if misused.

60323-96-8

Post Buying Request

60323-96-8 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

60323-96-8 Usage

Uses

Used in Pharmaceutical Industry:
2-Chloro-5-methyl-4-nitropyridine-N-oxide is used as an intermediate in the synthesis of various pharmaceuticals for its unique chemical properties. Its presence in the molecular structure can contribute to the development of new drugs with potential therapeutic applications.
Used in Chemical Reactions:
2-Chloro-5-methyl-4-nitropyridine-N-oxide is used as a reagent in chemical reactions, particularly in the synthesis of complex organic compounds. Its reactivity and functional groups make it a valuable component in the creation of new chemical entities for research and development purposes.

Check Digit Verification of cas no

The CAS Registry Mumber 60323-96-8 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 6,0,3,2 and 3 respectively; the second part has 2 digits, 9 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 60323-96:
(7*6)+(6*0)+(5*3)+(4*2)+(3*3)+(2*9)+(1*6)=98
98 % 10 = 8
So 60323-96-8 is a valid CAS Registry Number.

60323-96-8SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 18, 2017

Revision Date: Aug 18, 2017

1.Identification

1.1 GHS Product identifier

Product name 2-chloro-5-methyl-4-nitro-1-oxidopyridin-1-ium

1.2 Other means of identification

Product number -
Other names 2-Chlor-5-methyl-4-nitro-pyridin-1-oxid

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:60323-96-8 SDS

60323-96-8Relevant academic research and scientific papers

IMPROVED METHODS, KITS, COMPOSITIONS AND DOSING REGIMENS FOR THE USE OF HETEROCYCLIC INHIBITORS OF ERK1 AND ERK2

-

, (2021/05/07)

The present application provides improved compositions, methods, kits and dosing regimens for the use of heterocyclic compounds and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, or stereoisomers thereof. These compositions, methods, kit

2-hydroxy-4-amino-5-picoline heterocyclic compounds

-

, (2017/01/23)

The invention discloses a 2-hydroxy-4-amino-5-methylpyridine heterocyclic compound which can be used as an intermediate for synthesizing an omeprazole compound. The invention further discloses a synthesis method of a 2-hydroxy-4-amino-5-methylpyridine heterocyclic compound. The synthesis method comprises four steps of synthesis of 2-chloro-5-methylpyridine nitrogen oxide, synthesis of 2-chloro-4-nitro-5-methylpyridine nitrogen oxide, synthesis of 2-chloro-4-amino-5-methylpyridine and synthesis of 2-hydroxy-4-amino-5-methylpyridine. The synthesis method of the 2-hydroxy-4-amino-5-methylpyridine heterocyclic compound disclosed by the invention is simple, reaction raw materials are low in price, and a synthesis route is environment-friendly.

HETEROCYCLIC INHIBITORS OF ERK1 AND ERK2 AND THEIR USE IN THE TREATMENT OF CANCER

-

, (2017/01/02)

The present application provides novel heterocyclic compounds and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful for inhibiting ERK1/2. By administering to a patient in need a

HETEROARYLS AND USES THEREOF

-

Paragraph 0843, (2013/07/05)

This invention provides compounds of formula IB: and also provides compounds of formulas ID, IIB, VB, and IIC: wherein HY, R1, R2, G5, G6, G7, G8, and G9 are as described in the specification. The compounds are inhibitors of VPS34 and/or PI3K and are thus useful for treating proliferative, inflammatory, or cardiovascular disorders.

Synthesis of heteroaryl-fused pyrazoles as P38 kinase inhibitors

Abbot, Sarah C.,Billedeau, Roland J.,Dewdney, Nolan J.,Gabriel, Tobias,Goldstein, David M.,McCaleb, Kristen L.,Soth, Michael,Trejo-Martin, Teresa Alejandra,Zecic, Hasim

experimental part, p. 2811 - 2826 (2010/04/25)

The synthesis of pyrazolo-pyridine, pyrimidine, pyrazine and pyridazine heterocycles is described. In addition, we report the utilization of 2,4-difluorophenoxide as a leaving group, to facilitate formation of the desired pyrazole adducts.

AMINOPYRIMIDINE COMPOUNDS AND THEIR SALTS, PROCESS FOR PREPARATION AND PHARMACEUTICAL USE THEREOF

-

Page/Page column 13, (2008/06/13)

The present invention provides aminopyrimidine compounds of formula (I) and their salts, wherein R1, R2, R3, R4, R5, R6, Q, Z, L, m, n are defined as the description, the methods for preparation thereof, the uses thereof and the pharmaceutical compositions comprising the effective amount of compounds of formula (I). The compounds of formula (I) and their salts can be used as protein kinase inhibitors.

FUSED PYRAZOLE AS p38 MAP KINASE INHIBITORS

-

Page/Page column 43, (2008/06/13)

Fused pyrazoles effective as p38 MAP kinase inhibitors, methods of making the compounds, and methods of using the compounds for treatment of p38 MAP kinase-mediated diseases.

PYRIDINE DERIVATIVES AND THEIR USE AS MEDICAMENTS FOR TREATING DISEASES RELATED TO MCH RECEPTOR

-

Page/Page column 54, (2010/10/20)

The present invention encompasses novel substituted pyridine compounds of Formula (I), which act as MCH receptor antagonists. These compositions and pharmaceutical compositions thereof are useful in the prophylaxis or treatment of improving memory function, sleeping and arousal, anxiety, depression, mood disorders, seizure, obesity, diabetes, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, binge eating disorders including bulimia, anorexia, mental disorders including manic depression, schizophrenia, delirium, dementia, stress, cognitive disorders, attention deficit disorder, substance abuse disorders and dyskinesias including Parkinson's disease, epilepsy, and addiction.

PYRROLE COMPOUNDS AS INHIBITORS OF ERK PROTEIN KINASE, SYNTHESIS THEREOF AND INTERMEDIATES THERETO

-

, (2010/02/14)

The present invention relates to compounds useful of inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.

Heteroaryl-fused pyrazolo derivatives and methods for using the same

-

Page/Page column 35; 44, (2010/02/13)

Compounds of the formula I: where A, B, X, Y, Z, k, R1, R2 and R3 are those defined herein, and compositions comprising the same. The present invention also provides methods for preparing compounds of formula I and using t

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 60323-96-8